Krishna Institute of Medical Sciences has allotted 77,02,182 convertible warrants on a preferential basis to key stakeholders at ₹779 per warrant. According to latest reports, the warrants were issued to Dr. Abhinay Bollineni (Promoter), Adwik Bollineni (Promoter) and Bharas Ventures LLP (a Promoter Group entity). The company received an upfront subscription payment of ₹1,499,999,944.50, which constitutes 25% of the total ₹6,000 crore issue price. The remaining 75% of the issue value will be payable on conversion within 18 months from the date of allotment.
The warrant allotment significantly strengthens KIMS's capital structure while maintaining promoter control. Upon full conversion within 18 months, the promoter and promoter group stake is expected to rise from 32.50% to 33.71%. This strategic capital injection ensures the hospital chain remains exceptionally well-capitalized to fund its aggressive expansion footprint across Mumbai, Nashik, and Bengaluru while keeping interest expenses firmly in check. The ₹1,499,999,944.50 upfront funding serves as a strategic liquidity cushion without increasing high-cost interest obligations, complementing the company's recent debt reduction efforts.
The allotment increases the combined shareholding of the promoter and promoter group from 32.50% to 33.71%, assuming full conversion of the warrants into equity shares. As per the latest disclosure, Dr. Abhinay Bollineni's individual stake rises from 0.06% (2,36,495 shares) to 0.81% (34,45,737 shares), while Mr. Adwik Bollineni's stake increases from 0.01% (40,640 shares) to 0.76% (32,49,882 shares). Bharas Ventures LLP acquires a fresh stake of 0.30% (12,83,698 shares). The structure allows promoters to increase their voting power and economic interest without immediate full capital outlay, aligning their long-term commitment with the company's future equity expansion.
The warrant allotment supports KIMS's ongoing deleveraging strategy following a ₹1,500 crore QIP executed in June 2026. As per multiple reports, the company utilized ₹1,125 crore of QIP proceeds to pay down high-cost outstanding debt, reducing net debt from ₹3,250 crore in March 2026 to ₹2,400 crore by July 2026. This comprehensive debt reduction, combined with the ₹1,499,999,944.50 upfront warrant funding, positions KIMS exceptionally well for its multi-city healthcare network expansion while maintaining strong balance sheet health.
KIMS demonstrated robust operational momentum with consolidated revenue growth of 35.3% YoY to ₹1,180 crore in Q1 FY27, though PAT declined to ₹37 crore due to pre-operative drags. The company reported total revenue rising 36.1% YoY to ₹1,196 crore driven by strong inpatient and outpatient volumes in Q1 FY27. This strong operational performance, combined with the secured ₹6,000 crore capital commitment from promoters, ensures KIMS remains well-positioned to scale its healthcare network across multiple cities while managing the initial operating losses from new facilities.
